Avalo Therapeutics (AVTX) Goodwill & Intangibles (2017 - 2026)

Avalo Therapeutics has reported Goodwill & Intangibles for 10 years, with the latest figure at $10.5 million in Q1 2026.

• For the quarter ending Q1 2026, Goodwill & Intangibles changed 0.0% year-over-year to $10.5 million; the trailing twelve-month figure through Mar 2026 stood at $10.5 million (changed 0.0% YoY), and the FY2025 full-year result was $10.5 million, changed 0.02% from the prior year.
• Goodwill & Intangibles for Q1 2026 stood at $10.5 million, roughly flat from $10.5 million in the prior quarter.
• The five-year high for Goodwill & Intangibles was $14.4 million in Q1 2022, with the low at $10.5 million in Q4 2024.
• Historically, Goodwill & Intangibles has averaged $12.1 million across 5 years, with a median of $10.5 million in 2023.
• Annual changes were most pronounced in 2023 — Goodwill & Intangibles declined 27.11% — and 2025, when it grew 0.02%.
• Avalo Therapeutics' Goodwill & Intangibles stood at $14.4 million in 2022, then decreased by 27.11% to $10.5 million in 2023, then slipped by 0.02% to $10.5 million in 2024, then climbed by 0.02% to $10.5 million in 2025, then changed by 0.0% to $10.5 million in 2026.
• The last three Goodwill & Intangibles figures came in at $10.5 million (Q1 2026), $10.5 million (Q4 2025), and $10.5 million (Q3 2025), per Business Quant data.